作者
Miguel Valderrábano, Leif E Peterson, Vijay Swarup, Paul A Schurmann, Akash Makkar, Rahul N Doshi, David DeLurgio, Charles A Athill, Kenneth A Ellenbogen, Andrea Natale, Jayanthi Koneru, Amish S Dave, Irakli Giorgberidze, Hamid Afshar, Michelle L Guthrie, Raquel Bunge, Carlos A Morillo, Neal S Kleiman
发表日期
2020/10/27
期刊
Jama
卷号
324
期号
16
页码范围
1620-1628
出版商
American Medical Association
简介
Importance
Catheter ablation of persistent atrial fibrillation (AF) has limited success. Procedural strategies beyond pulmonary vein isolation have failed to consistently improve results. The vein of Marshall contains innervation and AF triggers that can be ablated by retrograde ethanol infusion.
Objective
To determine whether vein of Marshall ethanol infusion could improve ablation results in persistent AF when added to catheter ablation.
Design, Setting, and Participants
The Vein of Marshall Ethanol for Untreated Persistent AF (VENUS) trial was an investigator-initiated, National Institutes of Health–funded, randomized, single-blinded trial conducted in 12 centers in the United States. Patients (N = 350) with persistent AF referred for first ablation were enrolled from October 2013 through June 2018. Follow-up concluded in June 2019.
Interventions
Patients were randomly assigned to catheter ablation alone (n = 158 …
学术搜索中的文章
M Valderrábano, LE Peterson, V Swarup… - Jama, 2020